NRx Pharmaceuticals (NRXP) Q2 FY26 earnings call

NRx Pharmaceuticals achieved significant pipeline and strategic milestones in Q2 FY26, advancing multiple drug candidates towards commercialization and expanding its therapeutic focus. Key developments include progress on ketamine approvals, a major military partnership for NRX-101, and the acquisition of a transformative portfolio of drugs for severe neurological conditions. The company is leveraging non-dilutive funding for new programs while strengthening its balance sheet to support near-term launches.